- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04295304
NR600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases (NR)
March 13, 2023 updated by: Nano Retina
Safety and Performance Evaluation of the NR600 System in Subjects With End-stage Inherited Outer Retinal Degenerative Diseases
The study objective is to demonstrate safety of the NR 600 System, and to evaluate the performance of the device in restoring visual activity of daily living in subjects with retinal degenerative diseases and severe visual impairment
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The NR600 is a retinal prosthetic system intended to provide electrical stimulation to the retina to induce visual perception in patients with severe to profound vision loss due to degenerative retinal disease.
The system is consisting of an autonomous epiretinal implant with penetrating electrodes, Glasses and a Clinician Station.
The implant is Infrared (IR) powered and is designed to convert visual input into well-defined electrical stimulation patterns suited to elicit neuronal retina activity.
All study subjects will be implanted with the device in one eye and will be followed for 18-months.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rigler
- Phone Number: +972747377640
- Email: dudur@nano-retina.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have confirmed diagnosis of end-stage hereditary outer retinal degeneration such as RP or cone-rod dystrophy
- Visual acuity in both eyes from light perception to no light perception
- Confirmed functional ganglion cells and optic nerve in the implanted eye
- History of useful vision
- Mentally competent
Exclusion Criteria:
- Diseases or condition that affect retinal and or optic nerve function
- Optic Nerve diseases
- Diseases or conditions that, in the judgement of the surgeon, impede the ability to implant the device or would prevent the system from functioning
- Dry eye
- Pre-disposition to eye rubbing
- Posterior pole severe staphyloma
- Strabismus superior to 10 prismatic diopter
- Severe nystagmus
- Corneal endothelium density < 1500 cells/mm2
- Refractive error ≥±8 diopters spheric and 3.5 diopter cylindric
- Currently pregnant (female subject) or inadequate contraceptive treatment in female subjects <50 years of age.
- Hyperthyroidism or hypersensitivity to iodine
- Neurological and/or psychiatric diseases (e.g. M. Parkinson, epilepsy, depression)
- Participation in another study with any investigational drug or device that may conflict with the objectives, follow-up or testing of this study
- Conditions likely to limit life to less than 1 year from time of recruitment to the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NR600 device implantation
Retinal surgery and implantation of epi-retinal prosthesis
|
Retinal surgery and implantation of epi-retinal prosthesis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety endpoint
Time Frame: within 9 months post implantation
|
Occurrence of serious adverse events related to the device and/or to the procedure
|
within 9 months post implantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Weinberger Dov, Prof., Retinal surgeon
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 17, 2020
Primary Completion (Actual)
March 9, 2023
Study Completion (Actual)
March 12, 2023
Study Registration Dates
First Submitted
March 2, 2020
First Submitted That Met QC Criteria
March 3, 2020
First Posted (Actual)
March 4, 2020
Study Record Updates
Last Update Posted (Actual)
March 15, 2023
Last Update Submitted That Met QC Criteria
March 13, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NR-DOC-14670
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Degeneration
-
Seoul National University Bundang HospitalUnknownAge-Related Macular Degeneration | Retinal DrusenKorea, Republic of
-
University of LuebeckCompletedAge-Related Macular Degeneration | Retinal FunctionGermany
-
Stanford UniversityBascom Palmer Eye InstituteCompletedMacular Degeneration | Retinal DrusenUnited States
-
Guardion Health Sciences, Inc.Western University of Health Sciences; Eye Clinic of AustinCompletedMacular Degeneration | Age-related Macular Degeneration | Retinal DrusenUnited States
-
Benha UniversityRecruitingMacula Lutea DegenerationUnited Arab Emirates
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationJapan
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationItaly
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationFrance
-
Sorlandet Hospital HFActive, not recruitingWet Macular DegenerationNorway
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationFrance
Clinical Trials on Retinal surgery with implantation of epi-retinal device
-
Duke UniversityNational Institute on Aging (NIA)Enrolling by invitationOptical Coherence Tomography of RetinaUnited States
-
Retina Implant AGCompletedRetinal Degeneration | Retinitis PigmentosaHong Kong
-
University of NottinghamUniversity Hospitals of Derby and Burton NHS Foundation TrustCompletedRetinopathy of PrematurityUnited Kingdom
-
Retina Implant AGCompletedRetinal Degeneration | Retinitis PigmentosaGermany, Hungary, United Kingdom
-
Retina GlobalVisionQuest Biomedical LLCCompletedDiabetic RetinopathyBolivia
-
Medical University of ViennaWithdrawn
-
Z Optics, Inc.Not yet recruitingCataract | Presbyopia | Intraocular Lens
-
The University of Hong KongJanssen, LPNot yet recruiting
-
Medical University of ViennaCompletedCataract | PseudophakiaAustria
-
Vold Vision P.L.L.CAlcon ResearchCompletedGlaucoma, Open-Angle | Cataract | IOLUnited States